Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 134

1.

Novel aspects of resistance to drugs targeted to dihydrofolate reductase and thymidylate synthase.

Banerjee D, Mayer-Kuckuk P, Capiaux G, Budak-Alpdogan T, Gorlick R, Bertino JR.

Biochim Biophys Acta. 2002 Jul 18;1587(2-3):164-73. Review.

2.

Molecular mechanisms of resistance to antifolates, a review.

Banerjee D, Ercikan-Abali E, Waltham M, Schnieders B, Hochhauser D, Li WW, Fan J, Gorlick R, Goker E, Bertino JR.

Acta Biochim Pol. 1995;42(4):457-64. Review.

3.

Drug-resistant dihydrofolate reductases: generation, expression and therapeutic application.

McIvor RS.

Bone Marrow Transplant. 1996 Dec;18 Suppl 3:S50-4. Review.

PMID:
8971409
4.

Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism.

Peters GJ, Backus HH, Freemantle S, van Triest B, Codacci-Pisanelli G, van der Wilt CL, Smid K, Lunec J, Calvert AH, Marsh S, McLeod HL, Bloemena E, Meijer S, Jansen G, van Groeningen CJ, Pinedo HM.

Biochim Biophys Acta. 2002 Jul 18;1587(2-3):194-205. Review.

5.

Cancer research: from folate antagonism to molecular targets.

Bertino JR.

Best Pract Res Clin Haematol. 2009 Dec;22(4):577-82. doi: 10.1016/j.beha.2009.09.004. Review.

PMID:
19959110
6.

Future potential of thymidylate synthase inhibitors in cancer therapy.

Lehman NL.

Expert Opin Investig Drugs. 2002 Dec;11(12):1775-87. Review.

PMID:
12457437
7.

The means to an end of tumor cell resistance to chemotherapeutic drugs targeting thymidylate synthase: shoot the messenger.

Berg RW, Ferguso PJ, DeMoor JM, Vincen MD, Koropatnick J.

Curr Drug Targets. 2002 Aug;3(4):297-309. Review.

PMID:
12102601
8.

Molecular basis of antifolate resistance.

Assaraf YG.

Cancer Metastasis Rev. 2007 Mar;26(1):153-81. Review.

PMID:
17333344
9.

Recent advances in classical and non-classical antifolates as antitumor and antiopportunistic infection agents: part I.

Gangjee A, Jain HD, Kurup S.

Anticancer Agents Med Chem. 2007 Sep;7(5):524-42. Review.

PMID:
17896913
10.

Resistance mechanisms to methotrexate in tumors.

Bertino JR, Göker E, Gorlick R, Li WW, Banerjee D.

Stem Cells. 1996 Jan;14(1):5-9. Review.

11.

Downstream molecular determinants of response to 5-fluorouracil and antifolate thymidylate synthase inhibitors.

Van Triest B, Pinedo HM, Giaccone G, Peters GJ.

Ann Oncol. 2000 Apr;11(4):385-91. Review.

12.
13.

Thymidylate synthase inhibitors in cancer therapy: direct and indirect inhibitors.

Rustum YM, Harstrick A, Cao S, Vanhoefer U, Yin MB, Wilke H, Seeber S.

J Clin Oncol. 1997 Jan;15(1):389-400. Review.

PMID:
8996166
14.

Drug resistance in colon cancer.

Gorlick R, Bertino JR.

Semin Oncol. 1999 Dec;26(6):606-11. Review.

PMID:
10606253
15.

The methotrexate story: a paradigm for development of cancer chemotherapeutic agents.

Huennekens FM.

Adv Enzyme Regul. 1994;34:397-419. Review.

PMID:
7942284
16.

Malarial (Plasmodium falciparum) dihydrofolate reductase-thymidylate synthase: structural basis for antifolate resistance and development of effective inhibitors.

Yuthavong Y, Yuvaniyama J, Chitnumsub P, Vanichtanankul J, Chusacultanachai S, Tarnchompoo B, Vilaivan T, Kamchonwongpaisan S.

Parasitology. 2005 Mar;130(Pt 3):249-59. Review.

PMID:
15796007
17.

Translational autoregulation of thymidylate synthase and dihydrofolate reductase.

Tai N, Schmitz JC, Liu J, Lin X, Bailly M, Chen TM, Chu E.

Front Biosci. 2004 Sep 1;9:2521-6. Review.

PMID:
15353304
18.

Cellular and molecular mechanisms of resistance to antifolate drugs: new analogues and approaches to overcome the resistance.

Takemura Y, Kobayashi H, Miyachi H.

Int J Hematol. 1997 Dec;66(4):459-77. Review. Erratum in: Int J Hematol 1998 Apr;67(3):333.

PMID:
9479873
20.

Anticancer antifolates: current status and future directions.

McGuire JJ.

Curr Pharm Des. 2003;9(31):2593-613. Review.

PMID:
14529544
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk